Andrew Millar raises an important issue in his letter. He points out that despite promising preclinical efficacy and toxicity data, combining conventional chemotherapy with an angiogenesis inhibitor, or alternatively an oncogene signalling inhibitor, can lead to unexpected toxicities and/or lack of increased efficacy. Millar cites important and sobering results. However, the question of whether and how to combine angiogenesis inhibitors with chemotherapy was not overlooked in our discussion of this issue. For example, as noted in our review, we, and subsequently others have previously reported that angiogenesis inhibitors can be combined with chemotherapeutic drugs in which the latter are administered on an 'antiangiogenic' or 'metronomic' dose and schedule — that is, more frequently than most conventional schedules and at significantly lower than maximum tolerated doses1,2,3,4,5,6. Administration of chemotherapeutic drugs in this manner is designed to maximize their anti-angiogenic effects, while at the same time reducing the severe and acute toxicities that are often associated with conventional, maximum tolerated dose regimens7.
Clinical trials of antiangiogenic (metronomic) chemotherapy are underway at present8,9. Depending on their outcome, such trials — along with additional preclinical studies — might conceivably lead to a fundamental re-appraisal of how targeted anticancer drugs, including angiogenesis inhibitors, should be combined with chemotherapeutic agents. Perhaps as implied by Millar, nothing less than a new paradigm might be required for these sorts of combination treatments10, at least when these two therapies are administered concurrently. Nevertheless, we feel that it is too early to make a recommendation about which type of chemotherapy to use with an angiogenesis inhibitor, if any, until more data has been obtained. In fact, Millar highlights the crucial need for small-animal tumour-therapy models which will provide a much better idea of what will happen in the clinical setting11. In this regard, a good start would be the use of experimental tumour models in which treatment of advanced (high tumour burden) metastatic disease is undertaken, as opposed to treatment of primary tumours or of only microscopic (low tumour burden) disease.
References
Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886, (2000).
Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).
Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).
Bello, L. et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61, 7501–7506 (2001).
Zhang, L. et al. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 62, 2034–2042 (2002).
Klement, G. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. Clin. Cancer Res. 8, 221–232 (2002).
Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7, 427–436 (2001).
Colleoni, M. et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73–80 (2002).
Kerbel, R.S., Klement, G., Pritchard, K.I. & Kamen, B.A. Continuous laboratory into the oncology clinic. Ann. Oncol. 13, 12–15 (2002).
Kamen, B.A., Rubin, E., Aisner, J. & Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935–2937 (2000).
Fidler, I.J. & Ellis, L.M. Chemotherapeutic drugs: more really is not better. Nature Med. 6, 500–502 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kerbel, R., Folkman, J. Reply to “Limitations of combination anti-angiogenesis and chemotherapy”. Nat Rev Cancer 2, 804 (2002). https://doi.org/10.1038/nrc905-c2
Issue Date:
DOI: https://doi.org/10.1038/nrc905-c2